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Abstract
Background The safe use of a prosthesis in activities of daily living is key for transfemoral amputees. However, the number 
of falls varies significantly between different prosthetic device types. This study aims to compare medical and economic con-
sequences of falls in transfemoral amputees who use the microprocessor-controlled knee joint C-Leg with patients who use 
non-microprocessor-controlled (mechanical) knee joints (NMPK). The main objectives of the analysis are to investigate the cost-
effectiveness and budget impact of C-Legs in transfemoral amputees with diabetes mellitus (DM) and without DM in Germany.
Methods A decision-analytic model was developed that took into account the effects of prosthesis type on the risk of falling 
and fall-related medical events. Cost-effectiveness and budget impact analyses were performed separately for transfemoral 
amputees with and without DM. The study took the perspective of the statutory health insurance (SHI). Input parameters 
were derived from the published literature. Univariate and probabilistic sensitivity analyses (PSA) were performed to inves-
tigate the impact of changes in individual input parameter values on model outcomes and to explore parameter uncertainty.
Results C-Legs reduced the rate of fall-related hospitalizations from 134 to 20 per 1000 person years (PY) in amputees without 
DM and from 146 to 23 per 1000 PY in amputees with DM. In addition, the C-Leg prevented 15 or 14 fall-related death per 1000 
PY. Over a time horizon of 25 years, the incremental cost-effectiveness ratio (ICER) was 16,123 Euro per quality-adjusted life 
years gained (QALY) for amputees without DM and 20,332 Euro per QALY gained for amputees with DM. For the period of 
2020–2024, the model predicted an increase in SHI expenditures of 98 Mio Euro (53 Mio Euro in prosthesis users without DM 
and 45 Mio Euro in prosthesis users with DM) when all new prosthesis users received C-Legs instead of NMPKs and 50% of 
NMPK user whose prosthesis wore out switched to C-Legs. Results of the PSA showed moderate uncertainty and a probability of 
97–99% that C-Legs are cost-effective at an ICER threshold of 40,000 Euro (≈ German GDP per capita in 2018) per QALY gained.
Conclusion Results of the study suggest that the C-Leg provides substantial additional health benefits compared with NMPKs 
and is likely to be cost-effective in transfemoral amputees with DM as well as in amputees without DM at an ICER threshold 
of 40,000 Euro per QALY gained.
Keywords Knee prosthesis · Transferomal amputation · Microprocessor-controlled knee C-Leg · Cost-effectiveness · 
Economic evaluation · Markov model
JEL Classification I19
Introduction
Patients suffering from peripheral vascular disease (PVD) 
and/or diabetes may experience a transfemoral amputation—
a major surgery—as a long-term consequence of their condi-
tion. Most of these patients require chronic medical interven-
tions and medication anyway. As amputation is the treatment 
of last resort, the majority of patients have often endured 
re-vascularization attempts and/or long-standing in- and 
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outpatient treatments of vascular and diabetic ulcers, or 
oftentimes even toe or forefoot amputations. Many patients 
also present other secondary conditions such as cardio-vas-
cular and/or cerebro-vascular diseases. In Germany, the pro-
portion of age-adjusted major amputations (above-ankle to 
hemipelvectomy) with diagnosed diabetes mellitus declined 
by 30.9% within 9 years (2005–2014), whereas minor ampu-
tations in this cohort increased by 25.4%. [1] Another publi-
cation reported comparable trends for the period 2005–2015: 
− 43% for hip joint/femoral amputation and − 36.9% for 
knee and lower leg amputation [2].
An amputation is a tremendous incision in personal life 
that affects the patient’s health and quality of life for the rest 
of his/her lifetime. Providing the most suitable individual 
prosthetic support for disability compensation and regain-
ing self-sufficient participation in normal/social life are the 
primary rehabilitation goals after transfemoral amputations 
[3]. The safe use of a prosthesis in activities of daily living 
is key for transfemoral amputees [4]. Several clinical and 
biomechanical studies as well as two systematic reviews 
[4–15] investigated the safety of using the microproces-
sor-controlled knee joint C-Leg (C-Leg). Compared with 
non-microprocessor-controlled (mechanical) knee joints 
(NMPK), the C-Leg reduced the number and frequency of 
stumbles and falls of up to 80% [6, 8, 9]. In addition, four 
studies [16–19] that analyzed the health-related quality of 
life (HRQoL) in prosthesis users found improvements in the 
HRQoL of 14–38% when patients were using the C-Leg 
instead of NMPKs.
However, production costs of C-Legs are higher than 
those of conventional NMPKs and C-Legs require additional 
funding by the payer, when they are reimbursed. Therefore, 
it is important to investigate whether the price of the C-Leg 
is justified by the additional benefits. Four studies [16–18, 
20] have assessed the cost-effectiveness of the C-Leg com-
pared to NMPKs. Three studies were from Europe [16–18] 
and one study from the US [20]. Results varied from the 
C-Leg-dominating NMPKs in a patient cohort with an aver-
age age of 45–46 years old (societal perspective) [18] to an 
ICER of close to 90,000 Euros per quality-adjusted life year 
(QALY) gained in a cohort of amputees aged 40+ years old 
at the time of first prosthesis (payer’s perspective) [17]. Only 
one study included the medical and economic consequences 
of falling, which had a major impact on the cost-effective-
ness of the C-Leg [20].
Due to the heterogeneous cost-effectiveness results and 
model assumptions in international economic studies and 
differences in cost structures, conclusions regarding the 
cost-effectiveness of C-Legs in Germany cannot be drawn 
from results of international studies. In addition, none of the 
economic studies investigated the impact of comorbidities 
on the cost-effectiveness of C-Legs. Several epidemiologi-
cal studies found an improved survival in patients without 
diabetes mellitus (DM) compared to patients with DM over 
a longer time horizon [21–24]. Differences in all-cause mor-
tality may have a major impact on the cost-effectiveness, 
since the benefits of the C-Leg add up over time. Therefore, 
the aim of our study is to assess the cost-effectiveness of 
the C-Leg compared to NMPKs in transfemoral amputees 
without DM and transfemoral amputees with DM from the 
perspective of the German SHI.
For German statutory health insurance companies, the 
information on the budget impact of new interventions is 
(currently) more important than estimates of the cost-effec-
tiveness, since information on the budget impact is more 
relevant for short-to-midterm budget plans of the companies. 
So far, no German budget impact analysis of C-Legs does 
exist. Hence, another objective of this study is to predict 
the impact of C-Legs on the budget of the German SHI in 
2020–2024.
Methods
A decision-analytic model was developed in Microsoft 
EXCEL 2016 to perform a cost-effectiveness and budget 
impact analysis of C-Legs vs. NMPKs for transfemoral 
amputees with or without DM in Germany.
Model structure
The decision-analytic model consists of three structural 
modules: population, fall events, prosthesis failure. The pop-
ulation module simulates the survival and aging of recently 
transfemoral amputated patients who received their initial 
leg prosthesis. It includes five age groups: 40–49 years old, 
50–59 years old, 60–69 years old, 70–79 years old and 80+ 
years old. The population is updated yearly (model cycle 
length = 1 year). Annual survival of amputees is computed 
in a multi-step process. First, prosthesis users who die from 
non-fall-related causes exit the simulation. The average 
annual population size is then calculated by summing up the 
number of survivors at the start and at the end of each year 
and dividing it by two (= half cycle correction). Based on the 
average annual population size, the fall events module—a 
simple decision tree—calculates the annual number of fall-
related events, including fatal falls. In the fall events module, 
patients can either experience a fall or not. Falls may require 
medical attention or do not affect the health of the faller. 
Medical falls are further classified as fatal medical falls or 
non-fatal medical falls, which can lead to hospitalization 
or outpatient treatment (see Fig. 1). Finally, the population 
module corrects the number of surviving amputees (at the 
end of the year) for fatal falls and calculates the new average 
annual population.
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The prosthesis failure module calculates the number of 
prosthesis revisions based on the estimated average annual 
population. The number of prosthesis revisions is a key input 
for determining the costs of prosthesis usage. It consists of 
a series of tunnel states (year 1 with prosthesis, year 2 with 
prosthesis, etc.) which track the number of years of surviv-
ing amputees since the initial prosthesis fitting or the last 
prosthesis revision to determine the time of the next pros-
thesis revision.
Figure 1 shows the structure and interactions of the dif-
ferent modules and the contribution of each module to the 
health economic analysis.
Cost‑effectiveness analysis
The cost-effectiveness analysis focuses on the projected 
number of new prosthesis users in 2020 who are 40+ years 
old. Cost-effectiveness was calculated separately for patients 
with or without DM. The time horizon of the analysis was 
25 years. Clinical and economic benefits were evaluated 
from the perspective of the German SHI. Quality-adjusted 
life years (QALY) gained served as primary, prevented 
medical falls, hospitalizations and fatal falls as secondary 
outcomes. Costs and QALYs were discounted by 3% accord-
ing to the recommendations of the Institute for Quality and 
Efficiency in Health Care (IQWiG) [25].
Budget impact analysis
The budget impact was computed for the time period of 
2020–2024 (time horizon of 5 years) from the perspective of 
the German SHI. Costs were not discounted [25]. The analy-
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Fig. 1  Structure of the decision-analytic model
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initial leg prosthesis between 2000 and 2024 and was per-
formed separately for patients with and without DM. In total, 
125 incident cohorts (five age groups; 25 years) entered the 
budget impact model. Surviving incident leg prosthesis users 
of the period 2000–2019 constituted the prevalent patient 
cohorts in the budget impact model. Methods for the pro-
jection of incident leg prosthesis users are described in the 
segment epidemiology.
In the base case analysis, we made the following assump-
tions regarding the market share of C-Legs:
– 2000–2019: all eligible transfemoral amputees receive 
NMPKs
– 2020–2024: 100% of incident prosthesis users receive 
C-Legs; 50% of NMPK prevalent users, whose leg pros-
thesis wears out, switch to C-Legs and the other half get 
a revised NMPK
Other market shares were applied in scenario analyses.
Estimation of the number of prosthesis users
To date, there is no German leg prosthesis registry. Hence, 
we estimated the number of leg prosthesis users based on 
observed amputation incidence rates in 2005–2017. We per-
formed a linear regression on the logged incidence rates to 
estimate time trends between 2005 and 2011 as well as 2012 
and 2017. Incidence rates were then projected for the peri-
ods 2000–2004 and 2018–2024, respectively. Case numbers 
were calculated using demographic data. Finally, the annual 
number of new prosthetic users was determined as follows:
  IPUnoDM: incident prosthesis users without DM;  IPUDM: 
incident prosthesis users with DM; TA: transfemoral ampu-
tations;  pTADM: proportion of transfemoral amputees with 
DM;  mTAnoDM: 30 day mortality in amputees without DM; 
 mTADM: 30 day mortality in amputees with DM; pSF: pro-
portion of successful fitting; pSHI: proportion of Germans 
in the SHI.
Estimates of time trends and results of the projections are 
presented in the supplementary material.
Data sources
Input parameter values were either obtained from public 
accessible databases, published peer reviewed articles or in 
case of prostheses prices and prosthesis survival times from 
Ottobock (manufacturer of the C-Leg and one of the world’s 
IPUnoDM = TA ⋅ (1 − pTADM) ⋅ (1 −mTAnoDM)) ⋅ pSF ⋅ pSHI,
IPUDM = TA ⋅ pTADM ⋅ (1 - mTADM) ⋅ pSF ⋅ pSHI.
leading producers of NMPKs). A literature review was per-
formed in PubMed, Cochrane Library and Google Scholar. 
References of identified studies were manually searched 
for additional publications. Prosthesis subject-specific pub-
lications in prosthetic and orthotic journals where identi-
fied manually. In addition, results of a literature review of a 
recently published health economic study [20] were consid-
ered. Input parameters are summarized in Table 1.
Epidemiology
The annual number of transfemoral amputations were taken 
from official DRG statistics (OPS codes 5-864.3-5-864.7) 
[26]. Demographic data were obtained from the Federal 
Statistical Office of Germany [27, 28]. We identified one 
German study that reported midterm survival of lower limb 
amputees [21]. Other German studies only reported in-hos-
pital-mortality [2]. Icks et al. [21] provided survival data for 
patients with and without DM up to 5 years after amputation. 
We fitted Weibull distributions to extrapolate data up to 10 
years after amputation and assumed a fixed mortality rate 
from the tenth year onwards. 30 day mortality data which 
were used in the estimation of the annual number of leg 
prosthesis were also taken from the study of Icks et al. [21].
Several studies investigated prosthesis use and prosthesis 
fitting rates in lower limb amputees [29–36]. However, most 
studies [30–32, 34–36] had a small sample size and/or did 
not report outcomes for different amputation levels. Davie-
Smith et al. [29] as well as Resnik et al. [33] found fit rates 
in transfemoral amputees of 21.6% and 19.2%, respectively. 
While Davie-Smith et al. [29] analyzed age effects separately 
for transfemoral and transtibial amputations, Resnik et al. 
[33] reported only a combined age coefficient. Hence, we 
applied data from Davie-Smith et al. [29]. Estimated age 
effects of both studies were comparable though (0.97 vs. 
0.98) [29, 33].
In 2018, around 72.8 Mio Germans (87.7%) were insured 
in the SHI [37].
Risk of falling and fall‑related medical events
In our model, the risk of falling depended on the prosthesis 
type, while the probability of a medical event following a 
fall was assumed to be independent of that type. We identi-
fied five clinical trials [4, 8–12] that compared the number 
of falls of MPK versus NMPK usage. Two of these trials 
[9, 12] provided patient level fall outcomes, while the other 
studies only reported average fall numbers over a specific 
time period. Due to the small sample size (n = 8) of the study 
by Wong et al. [12], we populated our model with data from 
Kahle et al. [9]. We excluded two outliers from the sample 
due to implausible model outcomes in 40–49 years old: for 
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Table 1  Model parameters
Parameter Base case estimate
Probabilistic analysis SourceDistribution Parameter
Population without diabetes mellitus 
Number of prosthesis users see supplementary material
Proportion of SHI insured 87.7% - - - [37]
Prosthesis 
fitting




Scale 0.097 - - -
[21]Shape 0.509 - - -
Relative risk TA 1.500 lognormal μ=0.382 σ=0.215
Age factor 1.050 lognormal μ=0.049 σ=0.005
Population with diabetes mellitus 
Number of prosthesis users see supplementary material
Proportion of SHI insured 87.7% - - - [37]
Prosthesis 
fitting
Prob. of successful fitting 21.6% beta α=94 β=342






Scale 0.220 - - -
[21]Shape 0.859 - - -
Relative risk TA 1.500 lognormal μ=0.382 σ=0.215
Age factor 1.050 lognormal μ=0.049 σ=0.005
Risk of falling per year
C-Leg
Proportion of fallers 26.3% beta α=5 β=14
[9]
Number of falls per faller 1.33 lognormal μ=0.275 σ=0.157
NMPK
Proportion of fallers 84.2% beta α=16 β=3
Number of falls per faller 2.43 lognormal μ=0.880 σ=0.121
OR of falling 4+ years after amputation 
compared to first 3 years 0.53
1 lognormal μ=-0.671 σ=0.269 [38]
Fall-related medical events
Proportion of medical falls 26.8% beta α=11 β=30 [39]
Proportion of fatal falls 
in medical falls
<65 years old 3.6% beta α=3 β=80 [43]65+ years old 6.9% beta α=11 β=148
Proportion of hospitalizations in medical non-
fatal falls 45.5% beta α=5 β=6 [39]
Prosthesis failure rate
C-Leg Year 1-5 0 - - - assumptionYear 6 1 - - -
NMPK Weibull 
function
Scale 0.254 lognormal μ=-1.389 σ=0.198
[16, 44]Shape 2.77 - - -
Discounting cost-effectiveness analysis (budget impact analysis) 
Health outcomes 3% (0%) - - - [25]Costs 3% (0%) - - -
Utilities
C-Leg2
<55 years old 0.807 beta α=262 β=63
[17]
55-64 years old 0.780 beta α=279 β=79
65+ years old 0.704 beta α=306 β=129
NMPK2
<55 years old 0.688 beta α=194 β=88
55-64 years old 0.698 beta α=193 β=84
65+ years old 0.626 beta α=192 β=115
QALY loss of hospitalization 0.271 beta α=18 β=48 [46]
QALY loss of outpatient treatment 0.043 beta α=24 β=535
Costs
C-Leg + 6 year repair package 29,645 € - - -
[44]NMPK 10,862 € - - -
Fatal fall 5,903 € Assumption: fatal fall costs = costs of hospital treatment
Hospitalization 7,229 € For calculations see supplementary material
Outpatient visit / treatment 784 € For calculations see supplementary material
1 An annual decline of 1−OR<4y vs 4+y
3−OR
<4y vs 4+y
 in the proportion of fallers is assumed during the first 4 years after amputation. Base case values for the ORs of 
falling for 2, 3 and 4 + years compared with the first year after amputation are 0.81, 0.62, 0.43
2 Utility in 50–59 years old: average of < 55 and 55–64 years old; utility in 60–69 years old: average of 55–64 and 65+ years old
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NMPKs, fall-related mortality would have been higher than 
the estimated all-cause mortality in 40–49 years old. Both 
outliers were younger than 40 years old and, therefore, did 
not belong to the target population of the analysis.
Long-term risk of falling in prosthesis users has not been 
evaluated yet. Based on data of lower limb amputees [38], 
we assumed that the proportion of fallers declined over time. 
According to Miller et al., the odds of experiencing a fall in 
the past 12 months decreased by 47% in patients who were 
amputated 4+ years ago [38]. We assumed an annual linear 





 ) in the first 4 years followed by a stable 
proportion.
Falls may either require medical attention or they do not 
affect the health of the faller (Fig. 1) [39]. We identified only 
one study that reported fall-related injuries in lower limb 
amputees [39]. According to Wong et al. [39], 26.8% of all 
falls had medical consequences. Chen et al. [20] calculated 
a lower proportion of medical falls (10.4%) based on three 
studies [40–42] in the elderly general US population. We 
tested this value in the sensitivity analysis. Hospitalization 
probability was 45.5% in Wong et al. [39] which was compa-
rable to the figure of 40% applied by Chen et al. [20]. Fatal 
falls did not occur in the study by Wong et al. [39]. Possible 
reasons could be the small sample size or the design of the 
study (self reported outcomes). However, one subject died 
due to unknown causes and 12 subjects were lost to follow-
up [39]. Hence, we applied the same fatal fall probabilities 
as Chen et al. [20]: 3.6% (of medical falls) in < 65 years old 
and 6.9% (of medical falls) in 65+ years old [43]. We tested 
different assumptions in the sensitivity analysis.
Prosthesis failure rates
The price of the C-Leg includes a 6-year maintenance pack-
age, which covers all repair costs. We assumed that C-Legs 
were replaced directly after the maintenance package had 
expired. For NMPKs, such a maintenance package does 
not exist. We calculated a mean NMPK survival time of 
3.5 years based on data from Ottobock [44]. Brodtkorb et al. 
[16] found an increasing risk of NMPK failure over time 
and estimated a Weibull distribution. We also applied a 
Weibull distribution to determine yearly failure probabilities 
of NMPKs. The shape parameter of the distribution (2.77) 
was taken from Brothkorb et al. [16]. The scale parameter 
(0.2543) was calculated based on the shape parameter and 
the mean survival time of 3.5 years. Brodtkorb et al. [16] 
estimated a lower mean survival time of 2 years, which 
would result in a higher number of NMPK revisions. Nair 
et al. [45] analyzed prosthetic episodes in 100 transfemo-
ral amputees. Over a time horizon of 10 years, transfemo-
ral amputees needed 0.98 new prostheses and 2.31 major 
repairs. Based on this data, we calculated a mean prosthesis 
survival time of 7.11 years for new prostheses and a mean 
survival time of 2.26 years for new prostheses and major 
repairs combined. We tested the impact of both survival 
times on the outcomes in the sensitivity analyses.
Utilities
We identified four studies [16–19] which reported utilities 
for C-Leg and NMPK users. Three studies [16–18] used the 
EQ-5D 3L and one study [19] the SF-36/SF-6D. Brodtkorb 
et al. [16] derived utility values directly from the visual 
analog scale of the EQ-5D which is not the standard method 
for generating utilities and does not reflect preferences of 
the society. We obtained utility values from Cutti et al. [17], 
since this study had the largest ample size and was the only 
study that reported utilities for different age groups. Utility 
values were comparable to findings of Gerzeli et al. [18].
We found one study [46] which reported utility decre-
ments for fall-related medical events. Hartholt et al. [46] 
collected HRQoL data at 2, 5 and 9 months after the fall 
incident for hospitalized and non-hospitalized patients. 
We used graph digitizing software (PlotDigitizer 2.6.3) to 
extract numerical data from plotted utility scores [46] of all 
patients presenting to the emergency department. Reported 
utility scores at 9 months after the fall incident were used to 
calculate utility decrements for hospitalized and non-hospi-
talized patients. Utility decrements were extrapolated up to 
1 year. Long-term HRQoL reductions of fall events were not 
included in the evaluation.
Costs
The price year of the study was 2019. Average prices of 
C-Legs and NMPKs were calculated based on data from 
Ottobock [47]. The price of the C-Leg included a 6-year 
maintenance package. Costs of medical falls were esti-
mated using a micro-costing approach. Resource utilization 
of hospitalized cases included hospital treatment, inpatient 
rehabilitation treatment and outpatient treatment after hos-
pitalization. We assumed that costs of fatal falls were equal 
to the costs of hospital treatment. Costs of outpatient treat-
ment were obtained from a German health economic study 
of osteoporosis patients [48] and adjusted for inflation based 
on the German consumer price index [49]. Long-term costs 
of falling were not included in the evaluation. A detailed list 
of cost components and cost calculations are provided in the 
supplementary material.
In the sensitivity analyses, we tested the impact of higher 
fall costs on the health economic outcomes. For this, we 
used results of US cost studies [50–52] adjusted for price 
level differences between the US and German healthcare 
sectors [53] and inflation [49].
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Sensitivity analyses
Univariate and a probabilistic sensitivity analyses (PSA) were 
performed to investigate the impact of changes in individual 
input parameter values on model outcomes and to explore 
parameter uncertainty. The PSA was run with 10,000 itera-
tions. Base case estimates, probability distributions including 
parameters and references are summarized in Table 1.
Results
Falls and fall‑related events
In amputees without DM, the predicted incidence rates of 
falls were 178 per 1000 person years (PY) among C-Leg 
users and 1102 per 1000 PYs among NMPK users. In 
amputees with DM, incidence rates of falls were 203 per 
1000 PYs and 1201 per 1000 PYs, respectively. The major 
decrease in falls resulted in substantially reduced incidence 
rates of fall-related medical events among amputees using 
C-Legs compared with NMPK users: 3 vs. 17 fatal falls and 
20 vs. 134 hospitalizations per 1000 PYs in amputees with-
out DM as well as 3 vs. 18 fatal falls and 23 vs. 146 hospi-
talizations per 1000 PYs in amputees with DM. On average, 
C-Leg users without DM gained 1.96 life years (LYs) and 
C-Leg users with DM 0.55. Health outcomes of the base 
case analysis are shown in Table 2.
Cost‑effectiveness analysis
Health outcomes and costs were substantially higher in 
amputees without DM due to the lower overall survival 
of patients with DM. Discounted QALY gains of C-Leg 
usage were 1.74 in patients without DM and 0.92 in patients 
with DM. Discounted additional costs were 27,976 Euros 
in amputees without DM and 18,660 Euros in patients with 
DM. Prosthesis costs were the main cost driver among 
C-Leg users and constituted around 97% of the overall 
costs. Among NMPK users, costs of fall-related medical 
events amounted to 25–26% of total SHI costs (see Table 2). 
The ICER of C-Legs compared with NMPKs was 16,123 
Euros per QALY gained in patients without DM, 20,332 
Euros per QALY gained in patients with DM and 17,820 
Euros per QALY gained for both patient groups combined. 
Cost-effectiveness of C-Legs decreased with amputation 
age. The increase in ICER values intensified in 70+ years 
old and was more pronounced in patients with DM (see 
Fig. 2).
Table 2  Base case results (including 2.5% and 97.5% quantiles of the probabilistic sensitivity analysis)
Non-Vascular Vascular
Falls C-Leg NMPK C-Leg NMPK
Falls per 1,000 person years 178 (54-410) 1,102 (616-1,953) 203 (65-454) 1,201 (737-1,906)
Fatal falls per 1,000 person years 3 (1-8) 17 (6-39) 3 (1-8) 18 (6-37)
Hospitalizations per 1,000 person years 20 (4-59) 134 (38-316) 23 (5-65) 146 (45-320)
Outpatient treatments per 1,000 person years 25 (6-67) 161 (55-379) 28 (6-75) 176 (62-378)
Health outcomes (undiscounted) C-Leg NMPK C-Leg NMPK
Life years per patient 11.84 (10.50-14.48) 9.88 (9.02-10.70) 6.10 (5.38-7.18) 5.55 (5.02-6.16)
Quality adjusted life years per patient 8.63 (7.55-10.48) 6.27 (5.52-6.96) 4.50 (3.92-5.29) 3.39 (2.92-3.86)
Costs in Euro (undiscounted) C-Leg NMPK C-Leg NMPK
Prosthesis costs per patient 78,729 (71,893-92,833) 33,545 (25,543-43,395) 48,389 (44,995-53,485) 21,978 (17,514-27,736)
Fall-related medical costs 2,175 (487-6,396) 11,828 (4,242-25,718) 1,273 (304-3,536) 7,224 (2,754-14,969)
Total costs 80,904 (73,157-96,994) 45,373 (33,723-61,204) 49,662 (45,842-55,665) 29,202 (22,374-38,484)
Cost-effectiveness analysis (discounted by 3%) C-Leg vs NMPK C-Leg vs NMPK
QALYs gained 1.74 (0.91-3.24) 0.92 (0.51-1.59)
Additional costs (in Euro) 27,976 (19,034-36,363) 18,660 (12,563-23,544)
Incremental cost-effectiveness ratio (in Euro) 16,123 (8,095-32,631) 20,332 (9,465-40,721)
Budget impact analysis (undiscounted) C-Leg NMPK Difference C-Leg NMPK Difference
Year 1 (in Mio Euro) 47.2 (34.2-63.7) 30.9 (21.7-43.8) 16.3 (9.5-24.0) 35.0 (26.3-45.9) 22.5 (16.5-30.1) 12.5 (8.2-17.5)
Year 2 (in Mio Euro) 46.8 (34.0-62.1) 31.0 (21.7-44.0) 15.8 (9.3-22.3) 34.2 (25.8-44.2) 22.3 (16.3-29.8) 11.9 (7.9-16.3)
Year 3 (in Mio Euro) 43.8 (32.9-55.1) 31.1 (21.8-44.2) 12.7 (7.0-16.4) 32.0 (24.7-39.6) 22.0 (16.1-29.5) 10.0 (6.6-12.7)
Year 4 (in Mio Euro) 38.3 (29.9-46.8) 31.2 (21.8-44.3) 7.2 (-2.2-11.5) 28.6 (22.7-34.7) 21.7 (15.9-29.1) 6.9 (2.1-9.8)
Year 5 (in Mio Euro) 32.3 (25.3-40.6) 31.2 (21.8-44.4) 1.0 (-8.6-7.8) 25.4 (20.4-31.1) 21.5 (15.7-28.9) 3.9 (-0.7-7.4)
Total (in Mio Euro) 208.4 (159.4-263.0) 155.4 (108.7-220.7) 53.0 (27.5-70.0) 155.2 (120.9-192.8) 110.0 (80.5-147.4) 45.2 (30.1-58.1)
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Fig. 2  Cost-effectiveness of C-Legs in different age groups
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Budget impact analysis
Results of the budget impact analysis of C-Leg provision 
showed an increase in SHI costs of around 98 Mio Euro for 
the period of 2020–2024, 53 Mio Euro in patients without DM 
and 45 Mio Euro in patients with DM. Around 81% of the addi-
tional costs incurred in the first 3 years (2020–2022), when 
the majority of prosthesis users who received NMPKs before 
2020, switch to C-Legs. In addition, increasing costs of NMPK 
failures—C-Leg failures are covered by a 6-year maintenance 
package—and higher fall-related medical costs in NMPK users 
contributed to declining annual budget impacts between 2020 
and 2024 (see Table 2). Patients who were between 50 and 
79 years old at the time of amputation accounted for around 
80% of the total budget impact (see Fig. 3).
Providing C-Legs to all former NMPK users would 
increase the budget impact to about 196 Mio Euro (106 Mio 
Euro in prosthesis users without DM and 90 Mio Euro in 
prosthesis users with DM). If the market share of C-Legs 
was 25% in all new prosthesis users and only 12.5% of 
NMPK user switched to C-Legs, additional SHI expendi-
tures would amount to 24.5 Mio Euro (13.2 Mio Euro in 
prosthesis users without DM and 11.3 Mio Euro in pros-
thesis users with DM). Budget impacts for different market 
shares of the C-Leg are presented in Fig. 4.
Sensitivity analysis
Results of the PSA revealed moderate uncertainty in the 
ICER estimates and the budget impact of C-Legs (see Fig. 5 
and Table 2). The 2.5% and 97.5% quantiles (Q0.025, Q0.975) 
of the ICERs ranged from 8095 Euro to 32,631 Euro per 
QALY gained in C-Leg user without diabetes and from 
9465 Euro to 40,721 Euro per QALY saved in C-Leg user 
with diabetes. Assuming an ICER threshold of 40,000 Euro 
(≈ German per CAPITA GDP in 2018) per QALY gained, 
the probabilities that C-Legs are cost-effective were 99% in 
amputees without DM and 97% in amputees with DM. At 
an ICER threshold of 20,000 Euro per QALY gained, prob-
abilities were 70% and 44%, respectively. For both patient 
groups combined, C-Legs were cost-effective in 59% of the 
10,000 PSA iterations at an ICER threshold of 20,000 Euro 
per QALY gained. The Q0.025–Q0.975 intervals of the budget 
impact of C-Legs ranged from 27.5 to 70.0 Mio Euro in 
patients without diabetes and from 30.1 to 58.1 Mio Euro 
for patients with diabetes (Table 2).
Results of univariate and multivariate sensitivity analyses 
are shown in Fig. 6. Excluding the effects of falling had the 
highest impact on the cost-effectiveness of the C-Leg. ICERs 
for amputees with DM and without DM increased to 54,158 
Euro per QALY saved and 44,308 Euro per QALY saved, 
respectively. The proportion of medical falls and C-Leg 
prices had also a substantial impact on the cost-effectiveness 
results. High discount rates reduced the cost-effectiveness 
of C-Legs. However, the impact of discounting was limited 
(see supplementary material Table 6).
In the budget impact analyses, changes in cost parameter 
values (price of C-Legs, hospitalization costs) had the high-
est impact on the results. Excluding the effects of falling or 
reducing the proportion of medical falls increased the budget 
impact of C-Legs substantially. Increasing or decreasing 
the NMPK survival time resulted in major reductions in the 
budget impact of C-Legs (see Fig. 6).
Discussion
This study is the first health economic evaluation of micro-
processor-controlled knee prosthesis that analyzed the cost-
effectiveness in amputees with different etiologies (DM or 
no DM). C-Legs provided higher health benefits and had a 
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Fig. 4  Budget impact of C-Legs for different market shares
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expectancy of this patient group. However, the higher life 
expectancy also increased costs and the budget impact of 
patients without DM. Higher mortality and lower utility val-
ues reduced the additional benefits and the cost-effectiveness 
of C-Legs in older compared with younger amputees. The 
negative impact of age on the additional benefits and cost-
effectiveness of C-Legs has also been reported in an Ital-
ian health economic analysis [17]. Overall, the ICER was 
16,132 Euro per QALY gained in amputees without DM 
and 20,332 Euro per QALY gained in amputees with DM.
Several clinical and biomechanical studies [4–15] investi-
gated the safety of the C-Leg compared to NMPKs. Results 
of these studies reported a reduction in falls and stumbles 
when patients used C-Legs instead of NMPKs. Our analy-
sis showed that the effects of prosthesis type on falling and 
fall-related medical events have a major impact on the addi-
tional benefits and cost-effectiveness of C-Legs. Excluding 
these effects would result in a 2.7-fold increase in the ICER 
estimates according to our study. However, so far, only one 
other health economic analysis [20] included the medical 
and financial consequences of falling.
The design of our study is comparable to the analysis of 
Chen et al. [20] who estimated a base case ICER of 11,606 
US-Dollars per QALY gained [20]. Chen et  al. applied 
higher costs of fall-related medical events which was the 
main reason for the lower ICER compared with our study. 
Both models predicted comparable incidence rates of fall-
related medical events. While we assumed a higher propor-
tion for falls that require medical attention (26.8% derived 
from Wong et al. [39] vs. 10.4% in Chen et al. [20]), the 
applied number of falls per faller was lower in our base case 
analysis due to the exclusion of two outliers from the study 
sample of Kahle et al. [9]. Chen et al. [10] calculated the 
proportion of medical falls based on data of the general 
elderly population. Despite the much lower sample size, we 
considered results of Wong et al. [25] being more appropri-
ate for our analysis, since the study only included subjects 
with lower limb amputations. In the sensitivity analysis, 
we changed the proportion of fall-related medical events to 
10.4%. As a result, the ICER increased to 27,100 Euros per 
QALY gained in amputees without DM and to 34,500 Euros 














































   
























































   
   
   
   












Willingness to pay per QALY gained
C-Leg NMPK
a Scatter plot: prosthesis users without diabetes mellitus b Scatter plot: prosthesis users with diabetes mellitus 
c Cost-effectiveness acceptibility: prosthesis users without diabetes mellitus d Cost-effectiveness acceptibility: prosthesis users with diabetes mellitus 
QALY: quality adjusted life year; NMPK: non-microprocessor controlled (mechanical) knee joints
Fig. 5  Results of the probabilistic sensitivity analysis
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Three other health economic evaluations [16–18] did not 
include the effect of C-Legs and NMPKs on falling and fall-
related events. Brodtkorb et al. reported the lowest base case 
ICER of all studies and the highest number of QALYs gained. 
Compared to our analysis and the other studies, Brodtkorb 
et al. assumed a three- to four-fold higher difference in utili-
ties between the C-Leg and NMPKs [16], which was the main 
reason for the lower ICER. In the base case analysis, Gerzeli 
et al. estimated an ICER of 35,971 Euros per QALY gained 
from the payer’s perspective [18]. The time horizon in the 
analysis of Gerzeli et al. was 5 years and a 5-year warranty 
package was assumed for the C-Leg. Hence, C-Leg replace-
ment costs did not incur which may explain the lower ICER 
compared with our study, when we excluded the effects of 
falling. We derived utility data from Cutti et al. who reported 
an ICER of about 51,000 Euros per QALY gained for the age 
group 65+ years old [17]. The study also had a time horizon 
of 5 years and effects of falling were not included.
Demonstrating cost-effectiveness is currently not a man-
datory requirement for reimbursement in the German SHI. 
Neither an official cost-effectiveness threshold nor empiri-
cal evidence on accepted ICERs do exist for Germany. 
Therefore, we compared ICER estimates with a threshold 
proposed by the WHO. WHO-CHOICE considers inter-
ventions that avert one DALY (comparable to gains of one 
QALY) for less than average per capita GDP very cost-effec-
tive [54]. At a threshold of 40,000 Euro (≈ average German 
per Capita GDP in 2018) per QALY gained C-Legs were 
very likely to be cost-effective. In another very restrictive 
scenario, we explored the cost-effectiveness of C-Legs at 
a much lower threshold of 20,000 Euro (≈ half the aver-
age German per Capita GDP in 2018) per QALY gained. 
In this case, the probability that C-Legs were cost-effective 
decreased to 70% in amputees without DM and to 44% in 
amputees with DM. For both patient groups combined, the 
probability that C-Legs are cost-effective at a threshold of 
20,000 Euro per QALY gained was 59%.
The main limitations of our study are the lack of German 
utility values for prosthesis users, long-term data on the risk 
of falling and health economic consequences of fall-related 
events as well as the parameter uncertainty regarding the risk 
and the medical consequences of falling in prosthesis users. 
Comparative studies that have investigated the risk of falling 
in prosthesis users [7, 9–12] had rather short follow-ups and 
0 € 10,000 € 20,000 € 30,000 € 40,000 € 50,000 € 60,000 €
Costs per quality adjusted life years gained
0 € 10,000 € 20,000 € 30,000 € 40,000 € 50,000 € 60,000 €
Costs per quality adjusted life years gained
a Incremental cost-effectivnees in amputees without diabetes mellitus b 
c d 
Incremental cost-effectivnees in amputees with diabetes mellitus
Base case: 16,123 € Base case: 20,332 €
Exclude the effects of falling
Proportion of medical falls: 10% (Chen et al)
Proportion of medical falls: 43% (upper 95% CI); 14% (lower 95% CI)
Price C-Leg: 23,716 Euro (-20%); 35,574 Euro (+20%)
Time to NMPK failure according to Brodtkorb: 2 years
Costs of hospitalization:  19,135 (Mundell et al)1
Prosthesis utilities NMPK:  lower 95% CI, upper 95% CI 
Time to NMPK failure: 2.26 years; 7.11 years2
Proportion of faller NMPK:  97% (upper 95% CI); 60% (lower 95% CI)
Prosthesis utilities C-Leg: upper 95% CI, lower 95% CI
OR proportion of faller 4+y after amputation:  0.87 (upper 95% CI); 0.30 (lower 95% CI)
Falls per faller NMPK:  3.10 (upper 95% CI); 1.87 (lower 95% CI)
Proportion of hospitalization: 77% (upper 95% CI); 17% (lower 95% CI)
NMPK price: 13,034 Euro (+20%); 8,689 Euro (-20%)
Proportion of fatal falls / medical falls in <65/65+ years old: 10%/12% (upper 95% CI); 1%/4% (lower 95% CI)
Proportion of faller C-Leg:  9% (lower 95% CI); 51% (upper 95% CI)
Risk of falling according to Wong et al.4
Falls per faller C-Leg: 0.88 (lower 95% CI); 1.94 (upper 95% CI)
Proportion of hospitalization: 35% (Mundell et al)
QALY loss hospialization:  0.38 (upper 95% CI), 0.17 (lower 95% CI)
Costs of fatal falls:  19,454 (Burns et al)1
Prosthesis utilities: C-Leg 0.75, NMPK 0.66 Gerzelli et al)
QALY loss outpatient tratment:  0.06 (upper 95% CI), 0.03 (lower 95% CI)
Costs of outpatient treatment:  1,033 (Kim et al 2016)1
Price C-Leg: 23,716 Euro (-20%); 35,574 Euro (+20%)
Costs of hospitalization:  19,135 (Mundell et al)1
Time to NMPK failure according to Brodtkorb: 2 years
Exclude the effects of falling
Proportion of medical falls: 10% (Liu et al)
NMPK price: 13,034 Euro (+20%); 8,689 Euro (-20%)
Proportion of medical falls: 43% (upper 95% CI); 14% (lower 95% CI)
Time to NMPK failure: 2.26 years2
Time to NMPK failure: 7.11 years2
Proportion of hospitalization: 77% (upper 95% CI); 17% (lower 95% CI)
Proportion of faller NMPK:  97% (upper 95% CI); 60% (lower 95% CI)
OR proportion of faller 4+y after amputation:  0.87 (upper 95% CI); 0.30 (lower 95% CI)
Falls per faller NMPK:  3.10 (upper 95% CI)**; 1.87 (lower 95% CI)
Risk of falling according to Wong et al.4
Proportion of hospitalization: 35% (Mundell et al)
Proportion of fatal falls / medical falls in <65/65+ years old: 10%/12% (upper 95% CI); 1%/4% (lower 95% CI)
Costs of fatal falls:  19,454 (Burns et al)1
Proportion of faller C-Leg:  9% (lower 95% CI); 51% (upper 95% CI)
Falls per faller C-Leg: 0.88 (lower 95% CI); 1.94 (upper 95% CI)
Costs of outpatient treatment:  1,033 (Kim et al 2016)1
Base case: 53.0 Million Euros Base case: 45.2 Million Euros
 Budget impact in amputees without diabetes mellitus  Budget impact in amputees with diabetes mellitus
20 30 40 50 60 70 80
Budget Impact in Million Euro 
20 30 40 50 60 70 80
Budget Impact in Million Euro
1   US costs adjusted for price level differences and inflated to the price year 2019
2   New prosthesis + major repair (time to failure 2.26 years), new prosthesis (time to failure 7.11 years); Nair et al.
3   Proportion of faller C-Leg: 12.50%; Proportion of faller NMPK: 87.50%; Falls per faller C-Leg: 2.00; Falls per faller NMPK: 1.86
Fig. 6  Results of the univariate and multivariate sensitivity analyses
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small sample sizes. The only study that investigated fall con-
sequences in prosthesis users [39] also had a small sample 
size. Small sample sizes typically result in high parameter 
uncertainties and the lack of long-term data induces addi-
tional uncertainty. Hence, future research should focus on 
conducting comparative trials with larger sample sizes and 
longer trial durations. Establishing a clinical leg prosthesis 
register in Germany could also be very useful for the collec-
tion of more robust input data for health economic evalua-
tions. Utility estimates were relatively stable across studies 
[16–18]. We used utility data from the most recent study 
[17] with the lowest utility difference between the C-Leg 
and NMPKs.
We did not include economic- and health-related long-
term consequences of medical fall events in our analysis. 
The inclusion of long-term costs and long-term disutility of 
severe fall injuries would increase the benefits of the C-Leg 
and would improve its cost-effectiveness due to the superior 
safety of microprocessor-controlled knees compared with 
NMPKs. Adopting the German societal instead of the SHI 
perspective is likely to further improve the health economic 
outcomes of the C-Leg compared with NMPKs. Gerzeli 
et al. [18] reported a substantial reduction of indirect costs 
in C-Leg user compared with NMPK user. As a result, the 
C-Leg dominated the NMPK from the societal perspective, 
while the ICER from the payer’s perspective was around 
36,000 Euros per QALY gained.
Considering the results of the base case and sensitivity 
analyses of our study, the C-Leg is likely to be cost-effective 
compared to NMPKs in Germany, when applying cost-effec-
tiveness thresholds proposed by WHO-CHOICE. However, 
larger comparative trials and comprehensive German health 
economic data are required to provide more robust evidence 
regarding the cost-effectiveness of C-Legs.
Conclusion
The results of our study suggest that the C-Leg provides 
substantial additional benefits and is very likely to be cost-
effective in transfemoral amputees with and without DM 
from the perspective of the German SHI, when adopting an 
ICER threshold of around 40,000 Euro per QALY gained. 
For patients without DM and for both patient groups com-
bined, C-Legs may also be cost-effective at a threshold of 
20,000 Euro per QALY saved.
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